Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Galdakao – page 37

445 clinical trials in Galdakao, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Galdakao at a glance
445
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

445 trials in Galdakao

Open in trial search

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol
  • Sponsor:Astellas Pharma Global Development Inc.

Metastatic neoplasm

Not recruiting

Study on the Effectiveness of Tislelizumab and Spartalizumab in Patients with Advanced or Metastatic Cancer with High PD1 Biomarker Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Spartalizumab
  • Sponsor:Solti Group

Ischaemic stroke

Not recruiting

Study on the Safety of Afamelanotide for Patients with Acute Arterial Ischemic Stroke Ineligible for Standard Stroke Treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Afamelanotide
  • Sponsor:Clinuvel Europe Limited

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Liver transplant+1

Not recruiting

Study on Liver Transplantation: Comparing Custodiol-N Solution with a Drug Combination for Organ Preservation in Patients Undergoing Liver Transplant Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alanine
  • Sponsor:Dr. Franz Koehler Chemie GmbH

Breast cancer metastatic+1

Not recruiting

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Galdakao

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on breast cancer treatments, including trials for HER2-positive and triple-negative variants. Research encompasses innovative therapies for pancreatic adenocarcinoma and colon cancer.

  • Advanced breast cancer therapies
  • Neoadjuvant chemotherapy approaches
  • Metastatic cancer treatments

Multiple trials evaluating novel drug combinations and targeted therapies for improved patient outcomes.

02 Pulmonary Medicine

Comprehensive research into pulmonary fibrosis and respiratory conditions, with studies examining new treatments for COPD and pulmonary embolism management.

  • Interstitial lung diseases
  • Progressive pulmonary conditions
  • Respiratory therapy optimization

Innovative approaches to improve lung function and patient quality of life.

03 Cardiovascular Studies

Investigations into cardiomyopathy prevention and treatment, including trials for acute coronary syndromes and peripheral arterial disease management.

  • Genetic cardiac conditions
  • Vascular disease treatments
  • Antiplatelet therapy optimization

Focus on preventive strategies and improved treatment protocols for heart conditions.

04 Additional Therapeutic Areas

Studies addressing endocrine disorders, including hypothyroidism and its effects. Research on hepatic conditions and smoking cessation therapies.

  • Liver disease management
  • Addiction treatment
  • Hormonal disorders

Diverse therapeutic approaches targeting various medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.